Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.

Joshua F. Heiber, Xiangxi Xu, Glen N Barber

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.

Original languageEnglish
Pages (from-to)805-814
Number of pages10
JournalChinese Journal of Cancer
Volume30
Issue number12
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Oncolytic Virotherapy
Vesicular Stomatitis
Ovarian Neoplasms
Viruses
Pharmaceutical Preparations
Innate Immunity
Safety
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer. / Heiber, Joshua F.; Xu, Xiangxi; Barber, Glen N.

In: Chinese Journal of Cancer, Vol. 30, No. 12, 01.12.2011, p. 805-814.

Research output: Contribution to journalArticle

@article{1293d87fc53240e791f832ae8cae9304,
title = "Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.",
abstract = "In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.",
author = "Heiber, {Joshua F.} and Xiangxi Xu and Barber, {Glen N}",
year = "2011",
month = "12",
day = "1",
language = "English",
volume = "30",
pages = "805--814",
journal = "Cancer Communications",
issn = "1000-467X",
publisher = "BioMed Central Ltd.",
number = "12",

}

TY - JOUR

T1 - Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.

AU - Heiber, Joshua F.

AU - Xu, Xiangxi

AU - Barber, Glen N

PY - 2011/12/1

Y1 - 2011/12/1

N2 - In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.

AB - In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84865291086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865291086&partnerID=8YFLogxK

M3 - Article

C2 - 22059911

AN - SCOPUS:84865291086

VL - 30

SP - 805

EP - 814

JO - Cancer Communications

JF - Cancer Communications

SN - 1000-467X

IS - 12

ER -